Lilly offers cheaper insulin, pressuring competitors

Lilly will offer a new, lower cost insulin that is substitutable for Humalog at pharmacies. While at least one patient group says it's not enough, the move puts pressure on the pharma’s competitors.

Months of escalating political pressure have put insulin manufacturers at the forefront of a move away from drug rebates. Eli Lilly and Co. (NYSE:LLY) announced Monday it would roll out an authorized generic version of insulin lispro at half the list price of its Humalog insulin lispro. The authorized generic has a wholesale acquisition cost (WAC) of $137.35 for a 10 mL vial; Humalog's WAC is $274.70...